BII welcomes twelve new companies to its Venture Lab program
BioInnovation Institute (BII), an international non-profit foundation…
Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline
Series A financing led by Pfizer Ventures with new investors…
Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis
Germany is the first European country to launch ublituximab,…
Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress
Kling reports on advancing pipeline of therapeutic antibodies…
STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress
Data demonstrates pharmacological inhibition of METTL1 inhibits…
Researchers aim to advance quantum sensing to transform disease diagnosis and prevention
With its unprecedented precision, quantum sensing holds the potential…
Calliditas Year-end report, January – December 2023
OCTOBER – DECEMBER 2023(COMPARED TO OCTOBER – DECEMBER 2022)
…
Rejuvenate Biomed’s clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia
Cutting-edge therapy shows meaningful improvements in muscle…
Poolbeg Pharma plc – Board Role Change and Launch of Employee Performance Incentive Plan
15 February 2024 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…
DelSiTech and Tolmar Announce Global License and Development Agreement
Tolmar secures global license to DelSiTech’s Silica Matrix…
Poolbeg Pharma plc – Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Former Amryt team's arrival supports increasing focus upon Rare…
Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline
Co-founded by world leading dermatology experts and Medicxi
…
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
C21 is a potentially transformative therapy for the treatment…
Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®
First patients treated with H-Guard® at the National Institute…
Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.
BLADE-VG2 trial will evaluate the safety and efficacy of…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York